Therapeutic Benefits of Melatonin Against COVID-19.
Journal
Neuroimmunomodulation
ISSN: 1423-0216
Titre abrégé: Neuroimmunomodulation
Pays: Switzerland
ID NLM: 9422763
Informations de publication
Date de publication:
19 Jun 2023
19 Jun 2023
Historique:
received:
23
03
2023
accepted:
02
06
2023
medline:
20
6
2023
pubmed:
20
6
2023
entrez:
19
6
2023
Statut:
aheadofprint
Résumé
The assumption of the pineal hormone melatonin as a therapeutic use for COVID-19 affected people seems promising. It's intake has shown significant improvement in the patients' conditions. Higher melatonin titres in children may provide a protective shield against this disease. The hormone melatonin works as an anti-inflammatory, antioxidant, immunomodulator and strategically slows down the cytokine release which is observed in the COVID-19 disease, thereby improving the overall health of afflicted patients. The medical community is expected shortly to use remedial attributes like anti-inflammatory, anti-oxidant, anti-virals, etc of melatonin in the successful prevention and cure of COVID-19 morbidity. Thus, the administration of melatonin seems auspicious in the cure and prevention of this COVID-19 fatality. Moreover, melatonin doesn't seem to reduce the efficiency of approved vaccines against the SARS-CoV-2 virus. Melatonin increases the production of inflammatory cytokines and Th1 and enhances both humoral and cell mediated responses. Through the enhanced humoral immunity, melatonin exhibits antiviral activities by suppressing multiple inflammatory products such as IL6, IL1β, and TNFα, which are immmediately released during lung injury of severe COVID-19. Hence, the novel use of melatonin along with other antivirals as an early treatment option against COVID-19 infection is suggested. Here, we have chalked out the invasion mechanisms and appropriate implications of the latest findings concerned with melatonin against the virus SARS-CoV-2. Within the setting of a clinical intervention, the promosing compounds must go through a series of studies before their recommendation. In the clinical field, this is done in a time-ordered sequence, in line with the phase label affixed to proper protocol of trials: phase I - phase II and the final phase III . While medical recommendations can only be made on the basis of reassuring evidence, there are still three issues worth considering before implementation: representativeness, validity, and lastly generalizability.
Identifiants
pubmed: 37336193
pii: 000531550
doi: 10.1159/000531550
pmc: PMC10614475
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
The Author(s). Published by S. Karger AG, Basel.
Références
J Pineal Res. 1996 May;20(4):175-86
pubmed: 8836950
Eur J Med Chem. 2008 Sep;43(9):1926-44
pubmed: 18255198
J Pineal Res. 2020 Oct;69(3):e12683
pubmed: 32770854
Virus Res. 2020 Oct 2;287:198108
pubmed: 32768490
Recent Pat Endocr Metab Immune Drug Discov. 2012 Jan;6(1):30-9
pubmed: 22264213
Horm Behav. 2008 Sep;54(4):549-56
pubmed: 18586039
Indian J Biochem Biophys. 2008 Oct;45(5):289-304
pubmed: 19069840
Turk J Med Sci. 2020 Aug 11;50(6):1504-1512
pubmed: 32777902
Exp Dermatol. 2023 Apr;32(4):324-330
pubmed: 36437610
Curr Med Chem. 2015;22(33):3848-61
pubmed: 26310920
Adv Virus Res. 1997;48:1-100
pubmed: 9233431
Sleep Vigil. 2020;4(2):81-87
pubmed: 33015537
Ann Rheum Dis. 2005 Aug;64(8):1109-11
pubmed: 16014678
J Physiol Pharmacol. 2016 Apr;67(2):235-42
pubmed: 27226183
J Biol Chem. 2005 Jan 7;280(1):677-84
pubmed: 15504733
Vaccines (Basel). 2021 Sep 18;9(9):
pubmed: 34579276
Int J Mol Sci. 2021 Aug 11;22(16):
pubmed: 34445329
Sci STKE. 2001 Nov 06;2001(107):pe39
pubmed: 11698691
Life Sci. 2020 Jul 15;253:117739
pubmed: 32360622
Proc Natl Acad Sci U S A. 1987 Jun;84(11):3916-20
pubmed: 3035559
Int J Biol Sci. 2020 Mar 15;16(10):1724-1731
pubmed: 32226290
Br J Pharmacol. 1999 Mar;126(5):1237-45
pubmed: 10205014
J Pineal Res. 2014 Nov;57(4):381-4
pubmed: 25262626
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
J Med Virol. 2015 Apr;87(4):537-43
pubmed: 25611054
J Pineal Res. 2013 Oct;55(3):221-8
pubmed: 23679826
Life Sci. 2020 Sep 1;256:117902
pubmed: 32504754
Cleve Clin J Med. 2020 Jun 30;:
pubmed: 32606050
Psychopharmacology (Berl). 2021 Feb;238(2):611
pubmed: 33392622
Endocr Pract. 2021 Aug;27(8):850-855
pubmed: 34119679
J Recept Signal Transduct Res. 2015;35(4):238-48
pubmed: 25137035
J Pineal Res. 2018 Nov;65(4):e12525
pubmed: 30242884
Neurochem Res. 2006 Jul;31(7):925-32
pubmed: 16804753
Viruses. 2012 Jun;4(6):1011-33
pubmed: 22816037
Life Sci. 2020 Aug 15;255:117842
pubmed: 32454157
Life Sci. 2020 Jun 1;250:117583
pubmed: 32217117
Diseases. 2020 Nov 26;8(4):
pubmed: 33256258
Med Drug Discov. 2020 Jun;6:100044
pubmed: 32395713
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2018 Nov;34(11):1027-1031
pubmed: 30591112
Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5871-6
pubmed: 19321428
J Pineal Res. 2012 Oct;53(3):270-8
pubmed: 22506987
Trans R Soc Trop Med Hyg. 2002 May-Jun;96(3):348-51
pubmed: 12174794
Vet Immunol Immunopathol. 2018 Dec;206:1-8
pubmed: 30502907
Ital J Pediatr. 2013 Oct 03;39:61
pubmed: 24090288
Biomolecules. 2020 Aug 20;10(9):
pubmed: 32825327
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
Life Sci. 2020 Jul 15;253:117716
pubmed: 32334009
Front Med (Lausanne). 2020 May 15;7:226
pubmed: 32574327
Biomed Pharmacother. 2006 Apr;60(3):97-108
pubmed: 16527442
J Pineal Res. 2014 Apr;56(3):313-21
pubmed: 24499270
Int J Hypertens. 2013;2013:521783
pubmed: 23365722
Molecules. 2020 Sep 25;25(19):
pubmed: 32992875
Rev Med Virol. 2012 Sep;22(5):323-38
pubmed: 22511571
J Pineal Res. 2014 Sep;57(2):131-46
pubmed: 25060102
Oral Dis. 2010 Apr;16(3):242-7
pubmed: 19682319
Nanomedicine (Lond). 2020 Dec;15(29):2819-2821
pubmed: 33269948
Gene Ther. 2005 May;12(9):751-61
pubmed: 15772689
J Pineal Res. 2010 Mar;48(2):109-16
pubmed: 20070490
Br J Clin Pharmacol. 2008 May;65(5):797-8
pubmed: 18294335
J Pineal Res. 1993 Jan;14(1):1-10
pubmed: 8483103
BMC Res Notes. 2018 May 16;11(1):307
pubmed: 29769094
J Neuroimmune Pharmacol. 2022 Dec;17(3-4):425-426
pubmed: 34850335
Postgrad Med J. 2021 May;97(1147):312-320
pubmed: 32978337
Int J Infect Dis. 2022 Jan;114:79-84
pubmed: 34653660
Int Rev Immunol. 2020;39(4):153-162
pubmed: 32347747
Diseases. 2021 Sep 20;9(3):
pubmed: 34562971
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
Biochem Biophys Res Commun. 2020 Feb 17;:
pubmed: 32081428
Inflamm Regen. 2020 Oct 1;40:37
pubmed: 33014208
Mol Biol Rep. 2020 Oct;47(10):8229-8233
pubmed: 32920757
J Pineal Res. 2021 Aug;71(1):e12732
pubmed: 33759236
Rev Reprod. 1998 Jan;3(1):13-22
pubmed: 9509985
Physiol Rev. 1998 Jul;78(3):687-721
pubmed: 9674691
Rev Med Virol. 2020 May;30(3):e2109
pubmed: 32314850
J Pineal Res. 2023 Mar;74(2):e12847
pubmed: 36456538
Eur J Pharmacol. 2020 Sep 5;882:173329
pubmed: 32615182
N Engl J Med. 2000 Oct 12;343(15):1070-7
pubmed: 11027741
Expert Rev Clin Pharmacol. 2020 Sep;13(9):921-924
pubmed: 32893686
J Neuroimmune Pharmacol. 2020 Dec;15(4):572-573
pubmed: 32910359
J Virol. 2003 Aug;77(16):8801-11
pubmed: 12885899
Neurochem Res. 2003 May;28(5):681-6
pubmed: 12716016
Nutrients. 2020 Aug 24;12(9):
pubmed: 32847033
Science. 1988 Oct 7;242(4875):78-81
pubmed: 2845576